Nirogacestat
Product Detail
Product Tags
| Pack Size | Availability | Price (USD) |
| 10mg | In Stock | 350 |
| 100mg | In Stock | 680 |
| 1g | In Stock | 2950 |
Chemical Name:
(S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
SMILES Code:
CCC[C@H](N[C@@H]1CC2=C(C=C(F)C=C2F)CC1)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O
InChi Code:
InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1
InChi Key:
VFCRKLWBYMDAED-REWPJTCUSA-N
Keyword:
1290543-63-3；CAS:1290543-63-3；CAS：1290543-63-3；Nirogacestat；PF-3084014；PF3084014；PF 3084014
Solubility: Soluble in DMSO, not in water
Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Description:
Nirogacestat, also known as PF-03084014, is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors. Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Nirogacestat enhances docetaxel-mediated tumor response and provides a rationale to explore GSIs as adjunct therapy in conjunction with docetaxel for men with CRPC (castration-resistant prostate cancer).
Target: Reversible, non competitive, selective γ- Secretase inhibitor
